Medy-Tox: all 52 studies

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)CompletedNCT04157686Phase 3Results posted
• MT10109L in the Treatment of Glabellar LinesCompletedNCT03795922Phase 3Results posted
• MT10109L in the Treatment of Lateral Canthal LinesCompletedNCT03785145Phase 3Results posted
• MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar LinesCompletedNCT03732833Phase 3Results posted
• MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)CompletedNCT03721016Phase 3Results posted
• Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar LinesCompletedNCT01485601Phase 2Results posted
• MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb SpasticityCompletedNCT01313767Phase 3Results posted
• Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar LinesCompletedNCT05321979Phase 3
• A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar LinesCompletedNCT05217355Phase 2
• Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental FatCompletedNCT05195112Phase 3
• CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)CompletedNCT05164003Phase 1
• Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar LinesCompletedNCT05059587Phase 3
• Observational Study to Determine the Efficacy and Safety of Potenfill for Temporary Penile EnhancementCompletedNCT04496427
• Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®Status unknownNCT04281745Phase 4
• A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental FatCompletedNCT04144049Phase 2
• Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal LinesCompletedNCT04143854Phase 2
• Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar LinesCompletedNCT04143815Phase 2
• Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive BladderStatus unknownNCT04113941Phase 3
• Pivotal Clinical Study to Assess the Anti-adhesive Effect and Safety of ABT13107 Applied to Postoperative IntrauterineCompletedNCT04007211Not applicable
• MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb SpasticityCompletedNCT03908580Phase 4
• Efficacy and Safety Study of MT10107 in the Treatment of Glabella LineCompletedNCT03908008Phase 3
• Efficacy and Safety of MEDITOXIN® in Cervical DystoniaCompletedNCT03905304Phase 3
• Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy SubjectsCompletedNCT03905291Phase 1
• Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)CompletedNCT03894748Phase 2/3
• The Efficacy and Safety of Repeat-dose Potenfill for Temporary Penile EnhancementCompletedNCT03840070Not applicable
• The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar LinesCompletedNCT03837561Phase 3
• Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®CompletedNCT03796351Phase 1
• Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary HyperhidrosisCompletedNCT03760198Phase 3
• Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight SubjectCompletedNCT03759743Not applicable
• Neuramis® Volume Lidocaine for Volume Augmentation in the Mid-FaceCompletedNCT03754413Not applicable
• Neuramis® Deep Lidocaine Compared to YVOIRE® Volume Plus for Correction of Nasolabial FoldsCompletedNCT03753152Not applicable
• Anhidrotic Area and Safety of MEDITOXIN in Healthy Male ValunteersCompletedNCT03647982Phase 1
• Pharmacodynamic and Safety of MBA-P01 in Healthy Male VolunteersCompletedNCT03547141Phase 1
• Efficacy and Safety of Potenfill for Temporary Penile EnhancementCompletedNCT03512717Not applicable
• MEDITOXIN® Treatment in Subject With Benign Masseteric HypertrophyCompletedNCT03452345Phase 3
• Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive BladderCompletedNCT03371342Phase 1
• Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male VolunteersCompletedNCT03317717Phase 1
• MEDITOXIN® in Treatment of Crow's Feet LineCompletedNCT03317574Phase 3
• CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)CompletedNCT03289702Phase 3
• Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar LinesCompletedNCT03289169Phase 4
• Meditoxin® Treatment in Patients With Cervical DystoniaCompletedNCT03232320Phase 3
• Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential BlepharospasmCompletedNCT03216473Phase 3
• Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar LinesCompletedNCT03216408Phase 3
• Meditoxin® Treatment in Patients With Post Stroke Upper Limb SpasticityCompletedNCT02757404Phase 4
• Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial FoldCompletedNCT02751034Phase 3
• Neuramis® Volume Lidocaine Treatment in Patients With Loss of Mid-face VolumeCompletedNCT02721368Not applicable
• Medytoxin® Treatment in Patients With Benign Masseteric HypertrophyCompletedNCT02292472Phase 2
• Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical DystoniaCompletedNCT01588574Phase 2
• Efficacy and Safety Study of Neuramis in Correction of Nasolabial FoldCompletedNCT01585220Phase 3
• Efficacy and Safety Study of Meditoxin® to Treat Essential BlepharospasmCompletedNCT01259557Phase 4
• The Efficacy and Safety of MEDITOXIN® in Children With Cerebral PalsyCompletedNCT01256021Phase 4
• Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar LinesCompletedNCT01237977Phase 3

← Medy-Tox overview and focus areas